Observational study of newer immunotherapies for multiple myeloma in Norway
Studies how well and how safely newer immunotherapies work in routine care for myeloma.
Plain-language title generated from the registry record
Registry title: The Norwegian Immunotherapy in Multiple Myeloma Study
Key facts
- Where
- Ålesund, Arendal, Bærum, Bergen, Bodø, Drammen, Førde, Gjøvik, Haugesund, Kristiansand, Kristiansund, Levanger, Molde, Nordbyhagen, Oslo, Skien, Stavanger, Tønsberg, Tromsø, Trondheim, and Volda, NorwaySee the 23 sites
Where in Norway
- Ålesund hospital, Department of hematologyÅlesund, NorwayNot yet recruiting
- Sørlandet hospital ArendalArendal, NorwayNot yet recruiting
- Bærum HospitalBærum, NorwayNot yet recruiting
- Haukeland University HospitalBergen, NorwayNot yet recruiting
- Bodø HospitalBodø, NorwayNot yet recruiting
- Drammen hospitalDrammen, NorwayNot yet recruiting
- Førde HospitalFørde, NorwayNot yet recruiting
- Innlandet hospital trustGjøvik, NorwayNot yet recruiting
- Haugesund HospitalHaugesund, NorwayNot yet recruiting
- Sørlandet hospitalKristiansand, NorwayNot yet recruiting
- Nordmøre and Romsdal Hospital - KristiansundKristiansund, NorwayNot yet recruiting
- Levanger HospitalLevanger, NorwayNot yet recruiting
- Nordmøre and Romsdal Hospital - MoldeMolde, NorwayNot yet recruiting
- Akershus University Hospital (AHUS)Nordbyhagen, NorwayNot yet recruiting
- Diakonhjemmet HospitalOslo, NorwayNot yet recruiting
- Lovisenberg Diaconal HospitalOslo, NorwayNot yet recruiting
- Oslo Myeloma Center, Oslo University HospitalOslo, NorwayNot yet recruiting
- Telemark Hospital TrustSkien, NorwayNot yet recruiting
- Stavanger University HospitalStavanger, NorwayNot yet recruiting
- Vestfold Hospital TrustTønsberg, NorwayNot yet recruiting
- University Hospital of North NorwayTromsø, NorwayNot yet recruiting
- St. Olavs hospital HFTrondheim, NorwayTaking people
- Volda hospitalVolda, NorwayNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Olavs Hospital
- Trial code
- NCT06855121
- Record updated
- 20 July 2026
- Original description
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.Read full original descriptionShow less
The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Inclusion: Participants age ≥ 18 years; Prior diagnosis of one of the following; Multiple myeloma as defined according to IMWG criteria; Primary plasma cell leukemia as defined according to IMWG consensus definition; AL-amyloidosis as defined according to IMWG criteria; Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):; Teclistamab (Tecvayli); Elranatamab (Elrexfio); Talquetamab (Talvey); Idecabtagene vicleucel (ide-cel/Abecma); Ciltacabtagene autoleucel (cilta-cel/Carvykti).
Exclusion: None.